share_log

復星醫藥:海外監管公告 - 關於為控股子公司提供擔保的進展公告

FOSUN PHARMA: Overseas Regulatory Notice - Announcement on the Progress of Providing Guarantees to Subsidiaries

HKEX ·  Nov 22 18:46

Summary by Futu AI

2024年11月21日,复星医药宣布为其控股子公司提供多项担保,总金额折合人民币约3,063,392万元。此次担保涉及昆山健嘉、福州健嘉、复星雅立峰及复星健康等子公司。昆山健嘉将获得不超过人民币1,100万元的担保,福州健嘉的担保金额为人民币3,782万元,复星雅立峰和复星健康的担保金额分别为约55,236万元和213,109万元。公司强调,截至公告日,集团无逾期担保事项。此次担保的主要目的是支持子公司在融资和履约方面的需求。昆山健嘉与交通银行签订了融资合同,福州健嘉则与海通恒信开展融资租赁业务。复星雅立峰和复星健康则在法国外贸银行的共享授信额度下获得担保支持。公司表示,所有担保均在2023年...展開全部
2024年11月21日,复星医药宣布为其控股子公司提供多项担保,总金额折合人民币约3,063,392万元。此次担保涉及昆山健嘉、福州健嘉、复星雅立峰及复星健康等子公司。昆山健嘉将获得不超过人民币1,100万元的担保,福州健嘉的担保金额为人民币3,782万元,复星雅立峰和复星健康的担保金额分别为约55,236万元和213,109万元。公司强调,截至公告日,集团无逾期担保事项。此次担保的主要目的是支持子公司在融资和履约方面的需求。昆山健嘉与交通银行签订了融资合同,福州健嘉则与海通恒信开展融资租赁业务。复星雅立峰和复星健康则在法国外贸银行的共享授信额度下获得担保支持。公司表示,所有担保均在2023年度股东大会批准的额度范围内进行,风险相对可控。复星医药董事会认为,此次担保是基于集团经营需要,且被担保方仅限于控股子公司,风险可控。公司提醒投资者注意相关风险,特别是福州健嘉的资产负债率已超过70%。截至2024年11月21日,集团对外担保金额占2023年末净资产的67.05%。
On November 21, 2024, Fosun Pharma announced that it will provide multiple guarantees to its holding subsidiaries, totaling approximately RMB 30,633.92 million. The guarantees involved subsidiaries such as Kunshan Jianjia, Fuzhou Jianjia, Fosun Yalifeng, and Fosun Health. Kunshan Jianjia will receive guarantees of no more than RMB 11 million, Fuzhou Jianjia's guarantee amount is RMB 37.82 million, and the guarantee amounts for Fosun Yalifeng and Fosun Health are approximately RMB 552.36 million and RMB 2,131.09 million respectively. The company emphasized that as of the announcement date, the Group had no overdue guarantee matters. The main purpose of these guarantees is to support the financing and performance needs of the subsidiaries. Kunshan Jianjia has signed a financing contract with Bank of Communications, Fuzhou Jianjia has engaged in...Show More
On November 21, 2024, Fosun Pharma announced that it will provide multiple guarantees to its holding subsidiaries, totaling approximately RMB 30,633.92 million. The guarantees involved subsidiaries such as Kunshan Jianjia, Fuzhou Jianjia, Fosun Yalifeng, and Fosun Health. Kunshan Jianjia will receive guarantees of no more than RMB 11 million, Fuzhou Jianjia's guarantee amount is RMB 37.82 million, and the guarantee amounts for Fosun Yalifeng and Fosun Health are approximately RMB 552.36 million and RMB 2,131.09 million respectively. The company emphasized that as of the announcement date, the Group had no overdue guarantee matters. The main purpose of these guarantees is to support the financing and performance needs of the subsidiaries. Kunshan Jianjia has signed a financing contract with Bank of Communications, Fuzhou Jianjia has engaged in financing lease business with Haitong Hengxin. Fosun Yalifeng and Fosun Health have obtained guarantee support under the shared credit limit from Societe Generale. The company stated that all guarantees were within the approved limit of the 2023 shareholders' meeting and the risks are relatively controllable. The Fosun Pharma Board of Directors believes that these guarantees are based on the group's operational needs, and the guaranteed parties are limited to holding subsidiaries, thus the risks are controllable. The company reminds investors to pay attention to related risks, especially as Fuzhou Jianjia's asset-liability ratio has exceeded 70%. As of November 21, 2024, the amount of external guarantees granted by the Group accounted for 67.05% of the net assets at the end of 2023.

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.